Likarda

Likarda, with the slogan "Improving the Efficacy of Cellular Therapies," is a biotech company revolutionizing the delivery and optimization of cell therapies. The company has developed a groundbreaking method called Core Shell Spherification® (CSS) to coat cells with stealth hydrogels, protecting them from destruction and maintaining their viability in the intended location within the body. Unlike its competitors, Likarda boasts a library of over 50 different hydrogel formulations that complement Core Shell Spherification®, allowing for tailored coating molecules to match the specific requirements of therapeutic cells. These formulations range from durable, long-term coatings to degradable coatings that can deliver cells over varying periods, catering to exclusive therapeutic applications. Founded in 2012 and headquartered in the United States, Likarda's most recent investment was a Venture Round on 06 February 2024, with Missouri Technology Corporation (MTC) as the investor. The company's remarkable combination of visionary leadership, artistic scientific approach, and a commitment to ethical practices positions Likarda with well-defined long-range goals, coupled with opportunities for flexibility and growth in the future.